Penetration of tumor therapy interesting substances in non-vascularized metastases: Review of studies in multicellular spheroids

Current Cancer Therapy Reviews

Volumn 2, Issue 4, 2006, Pages 293-304

  Carlsson, Jörgen ^a   Gedda, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibodies; Cytostatic drugs; Epidermal growth factor; Metastases; Penetration; Review; Spheroids; Tumor cells

Indexed keywords

4 BORONOPHENYLALANINE; ANTINEOPLASTIC AGENT; BORON 10; BORON DERIVATIVE; CARBON 14; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXTRAN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HISTONE H3; INULIN; IODINE 125; LEUCINE; LEVO GLUCOSE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E4; MONOCLONAL ANTIBODY EGFR; RADIOISOTOPE; SERUM ALBUMIN I 125; SUCROSE; THYMIDINE; UNCLASSIFIED DRUG; VINBLASTINE;

AUTORADIOGRAPHY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TARGETING; FREEZE DRYING; HUMAN; HUMAN CELL; INCUBATION TIME; ISOTOPE LABELING; METASTASIS; MOLECULAR WEIGHT; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REVIEW;

EID: 33750687269     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339406778699213     Document Type: Review

References (55)

1. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50(3 Suppl): 814s-819s.
2. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271; 58-65.
3. Weinstein JN, Eger RR, Covell DG, et al. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 1987; 507: 199-210.
4. 1)2, and Fab in tumors. Cancer Res 1989; 49: 5656-63.
5. Carlsson J, Yuhas JM. Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res 1984; 95: 1-23.
6. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000; 36: 193-207.
7. Fracasso G, Colombatti M. Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol 2000; 36: 159-78.
8. Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol 1987; 113: 101-22.
9. Mueller-Klieser W. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol 1997; 273(4 Pt 1): C1109-23.
10. Mueller-Klieser W. Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 2000; 36: 123-39.
11. Santini MT, Rainaldi G, Indovina PL. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol 2000; 36: 75-87.
12. Sutherland RM, Durand RE. Radiation response of multicell spheroids - an in vitro tumour model. Curr Top Radiat Res Q 1976; 11: 87-139.
13. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988; 240: 177-84.
14. Acker H, Carlsson J, Durand R, Sutherland RM. Spheroids in cancer research. Springer-Verlag Berlin, 1984.
15. Bjerkvig R. Spheroid Culture in Cancer Research, Boca Raton, Florida CRC-Press 1992.
16. Carlsson J, Acker H. Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. Int J Cancer 1988; 42: 715-20.
17. Carlsson J, Nilsson K, Westermark B, et al. Formation and growth of multicellular spheroids of human origin. Int J Cancer 1983; 31: 523-33.
18. Nederman T, Carlsson J, Malmqvist M. Penetration of substances into tumor tissue - a methodological study on cellular spheroids. In Vitro 1981; 17: 290-8.
19. Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984; 13: 131-5.
20. Nederman T, Carlsson J, Kuoppa K. Penetration of substances into tumour tissue. Model studies using saccharides, thymidine and thymidine-5′-triphosphate in cellular spheroids. Cancer Chemother Pharmacol 1988; 22: 21-5.
21. Carlsson J, Daniel-Szolgay E, Frykholm G, Glimelius B, Hedin A, Larsson B. Homogeneous penetration but heterogeneous binding of antibodies to carcinoembryonic antigen in human colon carcinoma HT-29 spheroids. Cancer Immunol Immunother 1989; 30: 269-76.
22. Erlansson M, Daniel-Szolgay E, Carlsson J. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol 1992; 29: 343-53.
23. Lindstrom A, Carlsson J. Penetration and binding of epidermal growth factor-dextran conjugates in spheroids of human glioma origin, Cancer Biother 1993; 8: 145-58.
24. Pettersson OA, Carlsson J, Grusell E. Accumulation of 10B in the central degenerative areas of human glioma and colon carcinoma spheroids after sulfhydryl boron hydride administration. Cancer Res 1992; 52: 1587-91.
25. Pettersson OA, Olsson P, Lindstrom P, Sjoberg S, Carlsson J. Penetration and binding of L- and D-carboranylalanine in human melanoma spheroids. Melanoma Res 1993; 3: 369-76.
26. Nederman T, Acker H, Carlsson J. Penetration of substances into tumor tissue: a methodological study with microelectrodes and cellular spheroids. In Vitro 1983; 19: 479-88.
27. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 1251-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004; 58: 972-5.
28. Essand M, Nilsson S, Carlsson J. Uptake modification of a prostatic-reactive monoclonal antibody in prostatic carcinoma spheroids. Antibody, Immunoconjugates and Radiopharmaceuticals, 1995; 8: 179-98.
29. Essand M, Gronvik C, Hartman T, Carlsson J. Radioimmunotherapy of prostatic adenocarcinomas: effects of 131 I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995; 63: 387-94.
30. Andersson A, Holmberg A, Carlsson J, Carlsson J, Ponten J, Westermark B. Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int J Cancer 1991; 47: 439-44.
31. Olsson P, Lindstrom A, Carlsson J. Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int J Cancer 1994; 56: 529-37.
32. Sjoberg S, Carlsson J, Ghaneolhosseini H, et al. Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy. J Neurooncol 1997; 33: 41-52.
33. Haji-Karim M, Carlsson J. Proliferation and viability in cellular spheroids of human origin. Cancer Res 1978; 38: 1457-64.
34. Carlsson J, Brunk U. The fine structure of three-dimensional colonies of human glioma cells in agarose culture. Acts Pathol Microbiol Scand [A] 1977; 85A: 183-92.
35. Carlsson J, Collins P, Brunk U. Plasma membrane motility and proliferation of human glipma cells in agarose and monolayer cultures. Acta Pathol Microbiol Scand [A] 1978; 86:45-55.
36. Gati I, Bergstrom M, Csoka K, Muhr C, Carlsson J. Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines. Prostaglandins Leukot Essent Fatty Acids 1990; 40: 117-24.
37. Capala J, Acker H, Lindstrom A, Carlsson J. Effects of epidermal growth factor receptor blocking in cultured glioma spheroids. Anti-cancer Res 1994; 14: 45-53.
38. Essand M, Nilsson S, Carlsson J. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine. Anticancer Res 1993; 13: 1261-8.
39. Essand M, Lindholm CM, Silen A, Nilsson S, Carlsson J. The monoclonal anti-cytokeratin-8 antibody, 6D7, targets quiescent cells in prostatic carcinoma spheroids. Int J Oncol 1994; 5: 1293-99.
40. Sten-Knudsen O: Passive transport processes. In.: Giebish G., Tosteson D. C. and Ussing H. H. (eds.), "Membrane transport in biology", vol. 1 Springer Verlag, Berlin, pp. 5, 1978.
41. Carlsson J, Gedda L, Gronvik C, et al. Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int J Radiat Oncol Biol Phys 1994; 30: 105-15.
42. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987; 47: 1627-33.
43. Kwok CS, Cole SE, Liao SK. Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids. Cancer Res 1988; 48: 1856-63.
44. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004; 10: 4489-97.
45. Durand RE. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol 1990; 26: 198-204.
46. Steffen AC, Orlova A, Wikman M, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006 Mar 15; (Epub ahead of print).
47. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-8.
48. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-5.
49. Hjelstuen MH, Rasch-Halvorsen K, Bruland O, De L Davies C. Uptake, penetration, and binding of monoclonal antibodies with increasing affinity in human osteosarcoma multicell spheroids. Anti-cancer Res 1998; 18: 3153-61.
50. Kerr DJ, Wheldon TE, Hydns S, Kaye SB. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica 1988; 18: 641-8.
51. Gedda L, Ghaneolhosseini H, Nilsson P, et al. The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroids. Anticancer Drug Des 2000; 15: 277-86.
52. Nilsson P, Gedda L, Sjostrom A, Carlsson J. Effects of dextranation on the uptake of peptides in micrometastases: studies on binding of EGF in tumor spheroids. Tumour Biol 2001; 22: 229-38.
53. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003; 66:107-17. Review.
54. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52: 281-96.
55. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-57.